Duration of Anaesthesia Induction in Paediatric Patients: Prospective Observational Trial

NCT ID: NCT04527757

Last Updated: 2022-03-02

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2022-02-28

Brief Summary

Intravenous anaesthesia induction is nowadays considered as gold standard, mainly because of the possibility of the rapid therapeutic intervention while having secured i.v. line.

In the paediatric patients, apart from intravenous induction, it is also possible to use in the specific situations inhalation anaesthesia induction with sevoflurane (in the mixture with O2 + air, or O2 + N2O) and secure the i.v. line afterwards in the inhalation anaesthesia. This method is in the paediatric population currently preferred, mainly because of possible fear of the painful venipuncture.

Inhalation anaesthesia induction is possible only in patients without the risk of aspiration/regurgitation of stomach content and in patients without predicted difficult airway. Even if sedative premedication is used, during the inhalation induction excitation stage of the general anaesthesia variably appears, during which hemodynamic sympathoadrenal response and involuntary limbs movement might occur. When deepening inhalation anaesthesia, progression to surgical stage and automatic breathing onset appears. This subsequently facilitates to secure the venous access, without which is is not possible to secure the airway (in exception of the emergency situations - resuscitation).

Detailed Description

The aim of this prospective observational trial is to compare the duration of inhalation and intravenous anaesthesia induction in paediatric patients, who undergo elective surgical or diagnostic procedures. After the approval of the study by the Ethics Committee of the University hospital Brno and registration of the protocol at clinicaltrials.gov, the duration of inhalation and intravenous anaesthesia induction in the patients undergoing general anaesthesia in the Departement of paediatric anaesthesia and intensive care unit, University Hospital Brno in the term from 1.9.2020 until 30.6.2021 will be measured. Measurement will be done in all patients in the given time period, who will undergo elective surgical or diagnostic procedure. The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first end-tidal carbon dioxide (ETCO2) wave, after securing the airway with laryngeal mask or orotracheal intubation

For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O), for the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).

The type and the dose of the induction anaesthetic agent will be recorded (in the case of inhalation induction the dose of inhalation anaesthetic set on the vaporizer, in the case of intravenous induction the dose in mg/kg body weight).

The type and dose of the sedative premedication will be recorded, the number of attempts needed to secure i.v. line, success rate of securing the i.v. line while using Eutectic Mixture of Local Anesthetics (EMLA) patch and/or Buzzy (vibration device for patient distraction), the number of attempts needed to secure the airway, incidence of adverse events which might occur during anaesthesia induction (tachycardia, bradycardia, bronchospasm, laryngospasm).

Conditions

Anaesthesia Induction

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Paediatric patients with inhalation induction

The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).

Inhalation induction

Intervention Type: PROCEDURE

For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).

Paediatric patients with intravenous induction

The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O). For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).

Intravenous induction

Intervention Type: PROCEDURE

For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).

Interventions

Inhalation induction

For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).

Intervention Type: PROCEDURE

Intravenous induction

For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).

Intervention Type: PROCEDURE

Other Intervention Names

Anaesthesia inhalation induction; Anaesthesia intravenous induction

Eligibility Criteria

Inclusion Criteria

• paediatric patients scheduled for elective surgical or diagnostic procedure in the term from 10.9.2020 until 30.6.2021.

Exclusion Criteria

• Patients in the age from 0 to 1 month
• patients with predicted difficult airway
• emergency/urgent surgeries
• patients at the risk of regurgitation/aspiration of the stomach content
• procedures in which the airway will not be secured with laryngeal mask or orotracheal intubation
• cases were the time of induction can not be measured
• patients with intravenous line in situ

• Minimum Eligible Age: 28 Days
• Maximum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Brno University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Petr Štourač, MD

prof.MD,Ph.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Petr Štourač, prof. MD., Ph.D.

Role: STUDY_CHAIR

Faculty of medicince Masaryk University and University Hospital Brno

Locations

University Hospital Brno

Brno, , Czechia

Countries

Czechia

Other Identifiers

KDAR FN Brno 2020/09

Identifier Type: -

Identifier Source: org_study_id